NEVVI Medicare utilization intelligence
or

← back

Provider profile

HEGAZI, AMR MD

Hematology-Oncology · NPI 1366443152 · FREDERICK, MD

1
Groups
66
Codes · 2024
130,647
Disclosed services

HEGAZI, AMR is a Hematology-Oncology in FREDERICK, MD, a member of 1 medical group, who billed 66 distinct codes to Medicare Part B in 2024.

Groups: MARYLAND ONCOLOGY HEMATOLOGY PA (LAUREL, MD)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

130,647
disclosed services
66
codes billed to Medicare Part B
Prior year · CY2023 230,915 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J0897 Injection, denosumab, 1 mg
J9271 Injection, pembrolizumab, 1 mg
J1756 Injection, iron sucrose, 1 mg
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J1437 Injection, ferric derisomaltose, 10 mg
J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
80053 Blood test, comprehensive group of blood chemicals
88185 Flow cytometry technique for dna or cell analysis, each additional marker
J1100 Injection, dexamethasone sodium phosphate, 1 mg
82728 Ferritin (blood protein) level
83550 Iron binding capacity
83540 Iron level
J2919 Injection, methylprednisolone sodium succinate, 5 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
82784 Gammaglobulin (immune system protein) measurement
96372 Injection of drug or substance under skin or into muscle
36415 Insertion of needle into vein for collection of blood sample
J1626 Injection, granisetron hydrochloride, 100 mcg
J2469 Injection, palonosetron hcl, 25 mcg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
83615 Lactate dehydrogenase (enzyme) level
96413 Administration of chemotherapy into vein, 1 hour or less
J1750 Injection, iron dextran, 50 mg
96375 Injection of additional new drug or substance into vein
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J3489 Injection, zoledronic acid, 1 mg
83520 Measurement of substance using immunoassay technique
J1200 Injection, diphenhydramine hcl, up to 50 mg
85610 Blood test, clotting time
82232 Beta-2 microglobulin (protein) level
96361 Infusion into a vein for hydration, each additional hour
96415 Administration of chemotherapy into vein, each additional hour
86140 Measurement c-reactive protein for detection of infection or inflammation
82378 Carcinoembryonic antigen (cea) protein level
83735 Magnesium level
J7030 Infusion, normal saline solution , 1000 cc
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96360 Infusion into a vein for hydration, 31-60 minutes
99195 Drawing of blood for a medical problem
99212 Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
J3490 Unclassified drugs
96417 Administration of additional new drug or substance into vein, 1 hour or less
80048 Blood test, basic group of blood chemicals (calcium, total)
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
84153 Psa (prostate specific antigen) measurement, total
88184 Flow cytometry technique for dna or cell analysis, first marker
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
G0008 Administration of influenza virus vaccine
84443 Blood test, thyroid stimulating hormone (tsh)
84550 Uric acid level, blood
96374 Injection of drug or substance into vein
90653 Influenza vaccine, inactivated
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
38222 Biopsy and aspiration of bone marrow sample for diagnosis
82607 Cyanocobalamin (vitamin b-12) level

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.